Biogen Inc. (BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Ticker
BIIB
Exchange
Nasdaq
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$37.16B
52-week range
$160.36 - $261.00

Valuation

Share price
$251.41 (close of Nov 18, 2026)
P/E (TTM)
106.53x
Price to book
1.96x
Price to free cash flow
17.94x
Enterprise value
$43.66B
Book value per share
$128.03

Price performance

PeriodChange
1 day+0.25%
5 days-0.79%
1 month+8.06%
3 months+18.28%
6 months+31.00%
Year to date+42.85%
1 year+48.91%
3 years+10.27%
5 years-2.10%
10 years-20.69%
All time+7,945.12%

Short interest

As of
Oct 30, 2026
Short % of float
4.11%
Shares short
5.45M
Days to cover
3.96
Change since prior report
-0.86%
Source
FINRA consolidated short interest

Members of Congress who disclosed BIIB trades

Maria Elvira Salazar · Robert Bresnahan · Gilbert Ray Cisneros · Alan Armstrong · Kevin Hern

Super investors holding BIIB

Ken Griffin (Citadel) · Samantha McLemore (Patient Capital Management, LLC) · Hillman Capital (Hillman Capital Management, Inc) · Lee Ainslie (Maverick Capital LTD)

Profitability and growth

Return on equity
7.08%
Return on invested capital
6.28%*
Return on assets
4.39%
Return on capital employed
6.99%*
Gross margin
75.69%
Net margin
13.07%
EBITDA margin
26.33%
Revenue growth
2.22%
Net income growth
-20.79%
Free cash flow growth
-24.65%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
5.57%
Current ratio
1.95x
Net debt to EBITDA
3.98x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$9.89B
Cost of revenue
$2.40B
Gross profit
$7.49B
EBITDA
$2.60B
Net income
$1.29B
Earnings per share
$8.83
Research and development
$1.78B
Interest expense
$267.50M
Shares outstanding
146.50M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$9.89B$7.49B$1.29B$8.83
2024-12-31$9.68B$7.37B$1.63B$11.21
2023-12-31$9.84B$7.30B$1.16B$8.02
2022-12-31$10.17B$7.90B$3.05B$20.96
2021-12-31$10.98B$8.87B$1.56B$10.44
2020-12-31$13.44B$11.64B$4.00B$24.86
2019-12-31$14.38B$12.42B$5.89B$31.47
2018-12-31$13.45B$11.64B$4.43B$21.63
2017-12-31$12.27B$10.64B$2.54B$11.94
2016-12-31$11.45B$9.97B$3.70B$16.96

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3175.69%13.07%7.08%6.28%*
2024-12-3176.12%16.87%9.76%8.06%*
2023-12-3174.24%11.81%7.85%6.36%*
2022-12-3177.61%29.95%22.76%16.03%*
2021-12-3180.79%14.17%14.20%14.95%
2020-12-3186.57%29.76%37.44%19.22%
2019-12-3186.40%40.96%44.14%29.86%
2018-12-3186.50%32.93%34.00%23.53%
2017-12-3186.72%20.69%20.15%15.58%
2016-12-3187.08%32.34%30.53%20.99%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$3.82B$6.29B
2024-12-31$2.38B$6.30B
2023-12-31$1.05B$6.94B
2022-12-31$4.89B$6.28B
2021-12-31$3.80B$6.27B
2020-12-31$2.61B$7.43B
2019-12-31$4.48B$4.46B
2018-12-31$3.54B$5.94B
2017-12-31$3.69B$5.93B
2016-12-31$4.90B$6.51B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$2.05B$290.80M
2024-12-31$2.72B$291.20M
2023-12-31$1.27B$264.20M
2022-12-31$1.14B$254.10M
2021-12-31$3.38B$238.60M
2020-12-31$3.81B$198.30M
2019-12-31$6.56B$182.30M
2018-12-31$5.42B$157.50M
2017-12-31$3.68B$128.00M
2016-12-31$3.97B$154.80M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-28Sep 2026$2.06
2026-07-29Jun 2026$3.04
2026-04-29Mar 2026$2.95
2026-02-06Dec 2025$1.61
2025-10-30Sep 2025$3.89
2025-07-31Jun 2025$3.93
2025-05-01Mar 2025$3.26
2025-02-12Dec 2024$3.42

Filings and sources

Company website
biogen.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Organon & Co. (OGN) · Bristol Myers Squibb Co (BMY) · GSK plc (GSK) · Pfizer Inc (PFE) · Novo Nordisk A S (NVO) · Gilead Sciences, Inc. (GILD) · Amgen Inc (AMGN) · AstraZeneca plc (AZN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades